Zedira, Dr. Falk Pharma and the University of Mainz Hospital are to receive subsidy funding

27-Jun-2012 - Germany

The consortium consisting of Zedira, Dr. Falk Pharma and Prof. Schuppan of the medical department at the Johannes Gutenberg University in Mainz has announced that their collaboration on drug development of celiac disease is being subsidised under the CI3 excellence cluster of the German Federal Ministry for Education and Research (German abbreviation: BMBF).   The project involves preclinical and clinical development of the ZED1227 drug candidate, a low-molecular tissue transglutaminase blocker. The joint venture was commended as a flagship project of the excellence cluster for individualised immune intervention (CI3).

Celiac Disease is the most common chronic inflammation of the small intestine. The autoimmune disease is caused by alimentary gluten in genetically susceptible individuals.

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...